Latest revenue
$8.7M
as of 2026-03-31
Latest net income
$-17.1M
as of 2026-03-31
Net margin
-195.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think ABEO is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ABEO.
5-year trend
What this company does
ITEM 1. BUSINESS Business Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (“FDA”) approved ZEVASKYN® (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN®, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (“RDEB”), a serious and debilitating genetic skin disease. There is no cure for RDEB, and ZEVASKYN® is…
AI summary unavailable — showing raw filing excerpt
Generated from ABEO's filing dated 2026-03-17
Key risks
ITEM 1A. RISK FACTORS Our business, financial condition, financial results, and future growth prospects are subject to a number of risks and uncertainties, including those set forth below. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, financial results, and future growth prospects. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect us and our securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether such factors have occurred in the past or their…
AI summary unavailable — showing raw filing excerpt
Generated from ABEO's filing dated 2026-03-17
Profitability
Operating margin
-1536.9%
14.1%Net margin
1223.1%
179.0%Return on equity
44.7%
130.9%Return on assets
32.4%
155.4%Leverage
Debt / equity
0.38×
74.3%Long-term debt / equity
0.05×
83.4%Debt / assets
27.5%
53.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $8.7M | — | $-17.1M | -41.9% | -195.8% |
Q4 2025 2025-12-31 | — | — | $-8.4M | +9.3% | — |
Q3 2025 2025-09-30 | $400.0K | — | $-5.2M | +82.9% | -1290.3% |
Q2 2025 2025-06-30 | $400.0K | — | $96.8M | +1207.1% | 24201.0% |
Q1 2025 2025-03-31 | — | — | $-12.0M | +61.9% | — |
Q4 2024 2024-12-31 | — | — | $-9.3M | — | — |
Q3 2024 2024-09-30 | — | — | $-30.3M | -155.7% | — |
Q2 2024 2024-06-30 | — | — | $7.4M | +144.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ABEO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$3.0M
Net activity
−$3.0M
Distinct insiders
10
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ABEO
Institutional value
$62.5M
Total shares held
14.0M
Distinct holders
48
-55 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.2M | $14.3M | +35.7K (+1.1%) | Added |
| 2 | AIGH Capital Management LLC | 3.1M | $13.9M | +1.1M (+55.0%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $9.7M | — | New |
| 4 | KENNEDY CAPITAL MANAGEMENT LLC | 1.3M | $5.7M | +213.4K (+20.3%) | Added |
| 5 | NAN FUNG TRINITY (HK) LTD | 956.8K | $4.3M | +0 (+0.0%) | No change |
| 6 | CITIGROUP INC | 522.4K | $2.3M | +1.4K (+0.3%) | Added |
| 7 | Simplify Asset Management Inc. | 508.0K | $2.3M | +7.6K (+1.5%) | Added |
| 8 | VANGUARD FIDUCIARY TRUST CO | 339.5K | $1.5M | — | New |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 271.0K | $1.2M | — | New |
| 10 | JPMORGAN CHASE & CO | 266.5K | $1.1M | +245.2K (+1148.4%) | Added |
| 11 | UBS Group AG | 233.9K | $1.0M | +73.5K (+45.8%) | Added |
| 12 | GROUP ONE TRADING LLC | 209.6K | $939.0K | -114.4K (-35.3%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 193.6K | $867.5K | -632 (-0.3%) | Trimmed |
| 14 | SEI INVESTMENTS CO | 172.5K | $772.6K | +101.3K (+142.4%) | Added |
| 15 | LPL Financial LLC | 65.1K | $291.9K | +2.3K (+3.6%) | Added |
| 16 | Headlands Technologies LLC | 63.3K | $283.8K | — | New |
| 17 | Nuveen, LLC | 56.7K | $254.1K | +0 (+0.0%) | No change |
| 18 | RHUMBLINE ADVISERS | 55.8K | $250.2K | -84 (-0.2%) | Trimmed |
| 19 | DEUTSCHE BANK AG\ | 44.9K | $201.3K | +5.6K (+14.1%) | Added |
| 20 | DIMENSIONAL FUND ADVISORS LP | 34.4K | $154.0K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ABEO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.